SY-001 by CellOrigin Technology (Hangzhou) for Solid Tumor: Likelihood of Approval

As rare dis­ease drug re­search in­creas­es among large phar­ma com­pa­nies, so do their rep­u­ta­tions with rare dis­ease pa­tient groups. The lat­est sur­vey in Pa­tientView’s an­nu­al

Vi­ral dis­ease-fo­cused biotech Atea Phar­ma­ceu­ti­cals an­nounced a late-stage tri­al fail­ure for its nu­cleotide poly­merase in­hibitor, which it was in­ves­ti­gat­ing as a Covid-19 treat­ment. The Phase

The revenue for INKmune is expected to reach an annual total of $14 mn by 2039 in the US based off GlobalData’s Expiry Model. The